Ruxolitinib and survival improvement in patients with myelofibrosis
Leukemia
.
2015 Mar;29(3):739-40.
doi: 10.1038/leu.2014.282.
Epub 2014 Sep 24.
Authors
F Passamonti
1
,
A M Vannucchi
2
,
F Cervantes
3
,
C Harrison
4
,
E Morra
5
,
H Kantarjian
6
,
S Verstovsek
6
Affiliations
1
Division of Hematology, Department of Medicine, University Hospital Ospedale di Circolo e Fondazione Macchi, Varese, Italy.
2
Section of Hematology, Department of Critical Care, University of Florence, Florence, Italy.
3
Hematology Department, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain.
4
Guy's and St Thomas' NHS Foundation Trust, Guy's Hospital, London, UK.
5
Division of Hematology, Ospedale Niguarda Cà Granda, Milano, Italy.
6
Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA.
PMID:
25249013
DOI:
10.1038/leu.2014.282
No abstract available
Publication types
Letter
Comment
MeSH terms
Humans
Janus Kinases / antagonists & inhibitors*
Myeloproliferative Disorders / drug therapy*
Myeloproliferative Disorders / mortality*
Pyrazoles / administration & dosage*
Pyrazoles / adverse effects*
Substances
Pyrazoles
Janus Kinases